IV Dexamethasone Fails to Prevent Migraine Relapse in Kids

Research Summary

A study published in the journal Headache investigated whether adding a single dose of intravenous dexamethasone to standard migraine treatment could prevent relapse in children and adolescents after emergency department visits. This randomized, double-blind, placebo-controlled trial involved 116 patients aged 8-17 years at the CHU Sainte-Justine in Montréal. Participants received either dexamethasone or a placebo after standard therapy and were then discharged with oral naproxen. Results showed similar relapse rates within 48 hours for both the dexamethasone (39%) and placebo (44%) groups. Pain scores, school return, and healthcare visits were also comparable. The findings suggest no significant benefit from dexamethasone in preventing migraine relapse in this population.

Study Details

📄 Title: Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department.

👥 Research Team: Tourigny-Ruel G et al.

📚 Published In: Headache

📅 Publication Date: 2026 Apr 3

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.